EXHIBIT 10.26
▇▇▇ ▇▇▇▇▇ ▇▇▇▇ Tel: ▇▇ ▇▇▇ ▇▇▇-▇▇▇▇
Ottawa, Ontario Fax: ▇▇ ▇▇▇ ▇▇▇-▇▇▇▇
K2K 1X8 Canada
▇▇▇.▇▇▇▇▇▇▇▇▇▇.▇▇▇
(MDS NORDION LOGO)
November 21, 2006
▇▇▇▇▇ ▇▇▇▇▇▇-Coco
Director, R&D Operations
Molecular Insight Pharmaceuticals, Inc.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Dear ▇▇▇▇▇,
RE: AMENDMENT #3 TO AGREEMENT BETWEEN MDS NORDION, A DIVISION OF MDS (CANADA)
INC. ("MDS NORDION") AND MOLECULAR INSIGHT PHARMACEUTICALS, INC. (MIP) DATED
JUNE 14, 2004 (THE "AGREEMENT").
Reference is made to the Agreement between MDS Nordion and MIP dated the 14th
day of June, 2004 (the "Agreement").
In consideration of $1.00 and other valuable consideration the sufficiency of
which is hereby acknowledged, the parties desire to further amend the Agreement
and extend the term.
1. Section 16.1: Initial Term shall be amended to read as follows:
"The term of this agreement shall commence upon the Effective Date and,
unless terminated earlier pursuant to this agreement, or extended upon
mutual agreement of the parties, shall expire on December 31, 2007."
All other Terms and Conditions in this agreement shall remain in full force and
effect.
The foregoing amendment and agreement shall be effective as of the 26th day of
Nov., 2006.
In you agree with the foregoing, please execute this Agreement in the space
provided below.
-1-
[MDS Nordion LOGO]
MDS NORDION, A DIVISION OF MDS (CANADA) INC.
Per: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇
Name: ▇▇▇▇▇ ▇▇▇▇▇▇
Title: Senior Vice President
Sales & Marketing
We agree this 26th day of November, 2006
MOLECULAR INSIGHT PHARMACEUTICALS INC.
Per: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇
Name: ▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: Chief Operating Officer
-2-